Plasma Cell Dyscrasias: General Overview

Article written and reviewed by Dr Luca Moretti

Plasma cell dyscrasias constitute a heterogeneous group of neoplasms and preneoplastic conditions arising from the plasma cell compartment, whose terminally differentiated B-lineage cells are responsible for immunoglobulin synthesis. These disorders represent one of the most refined paradigms of hematologic biology: from physiological regulation of the antibody response to disruption of clonal control mechanisms, through the complex interaction among genetic and molecular abnormalities, the bone marrow microenvironment and systemic manifestations. Their clinical and scientific relevance is steadily increasing because of improved diagnostic techniques and progressive population aging.

Under physiological conditions, plasma cells may derive from both germinal-center responses and extrafollicular responses following antigenic stimulation, undergoing stringent selection and apoptotic control that maintain B-cell compartment homeostasis. When these controls are disrupted through multiple genetic and microenvironmental events, aberrant clonal proliferation may develop, often accompanied by production of a monoclonal immunoglobulin, known as the M-protein or paraprotein. The resulting spectrum includes plasma cell conditions ranging from MGUS, monoclonal gammopathy of undetermined significance, which is typically asymptomatic, to overt multiple myeloma and AL amyloidosis, as well as deposition diseases and rare related syndromes. Within the broader field of monoclonal gammopathies is also Waldenstrom macroglobulinemia, which is a lymphoplasmacytic lymphoma of the mature B-cell lineage.

Monoclonality is therefore a distinguishing, but not exhaustive, feature of plasma cell dyscrasias. Detection of a monoclonal component alone does not automatically imply active or progressive disease: the natural history of these conditions is characterized by a variable and sometimes unpredictable course, in which precursor stages may remain stable for decades or, conversely, progress to clinically aggressive disease.

Over recent decades, research into plasma cell dyscrasias has profoundly changed the traditional view of these disorders, leading to identification of new disease entities, classification of borderline forms such as monoclonal gammopathy of renal significance, MGRS, and recognition of mechanisms of extramedullary organ injury that extend far beyond direct neoplastic infiltration.

Understanding the physiological foundations, classification, pathogenetic implications and clinical consequences of plasma cell dyscrasias is now essential for hematologists, nephrologists, neurologists, cardiologists and all specialists involved in the care of affected patients. Genetic and phenotypic heterogeneity, the possibility of often subtle organ damage and the evolving nature of these clones require a multidisciplinary approach and continuous updating on advances in translational research.

The following sections examine the principal aspects of molecular biology, epidemiology, pathophysiology and classification of plasma cell dyscrasias, while the individual entities, including MGUS, multiple myeloma, AL amyloidosis, Waldenstrom macroglobulinemia, plasmacytoma, cryoglobulinemia, MGRS and rare syndromes, are discussed in dedicated monographic articles.

Plasma Cell Physiology and the Biological Basis of Dyscrasias

Understanding the nature of plasma cell dyscrasias requires starting from plasma cell biology, the biology of a terminally differentiated cell derived from the B lymphocyte. The physiological plasma cell is the culmination of a sophisticated sequence of activation, selection and differentiation induced by antigen contact, support from follicular T cells and the microenvironment of lymph-node germinal centers. Immunoglobulin diversity originates from V(D)J rearrangement, which occurs during early B-cell development; after antigen activation, somatic hypermutation and class switching, or isotype switching, occur in germinal centers and refine antibody specificity and class.

Plasma cells that migrate to the bone marrow are responsible for the sustained production of antibodies needed for long-term protection against pathogens. Homeostasis of the plasma cell compartment depends on a delicate balance between survival signals from bone marrow stromal cells, IL-6, BAFF and APRIL, and apoptotic signals that ensure elimination of unnecessary or autoreactive clones. At the molecular level, this balance is governed by regulatory pathways involving key transcription factors, including BLIMP1, XBP1 and IRF4, and systems that control responses to metabolic and genotoxic stress.

Pathological transformation of a plasma cell is the final result of a series of genetic and microenvironmental events that confer proliferative capacity, resistance to apoptosis, migratory ability and abnormal production of immunoglobulins or their fragments. The most important molecular events include:

• Translocations involving the immunoglobulin heavy-chain locus (IgH) and oncogenic genes, such as t(11;14), t(4;14) and t(14;16), which promote deregulated expression of cyclins, MMSET, MAF and other growth factors
• Mutations in driver genes (NRAS, KRAS, TP53, DIS3, BRAF) that sustain clonal growth and survival
• Numerical chromosomal abnormalities (hyperdiploidy, deletion of 13q or 17p, gain of 1q), often associated with progression and high cytogenetic risk
• Deregulation of signaling pathways (NF-kB, PI3K/AKT, MAPK) and pathological interaction with the bone marrow microenvironment (stromal cells, osteoclasts, endothelial cells)

These abnormalities, which often accumulate sequentially from the MGUS stage through transformation to multiple myeloma and beyond, generate the complex biological and clinical heterogeneity characteristic of plasma cell dyscrasias.

A distinctive pathophysiological feature of plasma cell dyscrasias is the ability of pathological plasma cells to reshape the bone marrow microenvironment to their own advantage by promoting angiogenesis, local immunosuppression and bone remodeling through osteoclast activation and osteoblast inhibition. The resulting environment supports clone survival and growth and contributes to systemic manifestations such as osteolysis, anemia, immunodeficiency and organ damage.

Finally, excessive production of monoclonal immunoglobulins, the M-protein, or free light chains may exert direct or indirect toxic effects on tissues and cause complications such as AL amyloidosis, deposition diseases (LCDD, HCDD), cryoglobulinemia and monoclonal gammopathy-associated nephritis. This highlights the importance of distinguishing the mere presence of an M-protein from its actual clinical pathogenicity, a central concept in the modern assessment of plasma cell dyscrasias.

Classification of Plasma Cell Dyscrasias

The WHO and ICC classifications distinguish plasma cell neoplasms from mature B-cell neoplasms. Within the broader clinical framework of monoclonal gammopathies, precursor conditions and syndromes defined by organ damage caused by the monoclonal protein are also considered.

The principal distinction is among:

• Asymptomatic precursor states, represented by monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM), conditions characterized by the absence of myeloma-defining events or attributable CRAB organ damage and by a variable risk of progression
• Overt plasma cell neoplasms, including multiple myeloma and plasmacytoma, either solitary or extramedullary, distinguished according to cytological features, site of growth and systemic manifestations
• Syndromes caused by deposition or toxicity of monoclonal immunoglobulins, such as AL amyloidosis, light-chain or heavy-chain deposition diseases (LCDD, HCDD) and monoclonal cryoglobulinemia, in which the M-protein causes organ damage through physicochemical and immune-mediated mechanisms
• Monoclonal gammopathies of clinical significance, such as monoclonal gammopathy of renal significance (MGRS) and monoclonal gammopathy of neurological significance (MGNS), defined by organ damage attributable to the monoclonal protein even when the clone does not meet thresholds for treatment of a hematologic neoplasm

This framework distinguishes conditions not only on the basis of tumor burden but, more importantly, according to the presence, nature and severity of organ damage mediated by the monoclonal component.

Multiple myeloma is the paradigmatic and most extensively studied plasma cell dyscrasia and is characterized by bone marrow infiltration, production of a monoclonal component, skeletal damage, anemia, renal failure and immunosuppression. It is accompanied by clinically and biologically distinct forms such as nonsecretory myeloma, light-chain myeloma and extramedullary myeloma, each with distinctive pathogenetic mechanisms and prognosis.

Waldenstrom macroglobulinemia is a lymphoplasmacytic lymphoma of the mature B-cell lineage with plasmacytoid differentiation, predominant production of monoclonal IgM and a clinical picture dominated by hyperviscosity syndrome, peripheral neuropathy and lymph-node or splenic involvement. Monoclonal cryoglobulinemia and deposition diseases are entities in which the clinical burden results more from tissue deposition or precipitation of the M-protein than from tumor proliferation itself.

A condition of major hematologic importance is MGUS, the most common preneoplastic condition in older adults. Only a minority of cases progress to myeloma or another neoplasm, but its identification and longitudinal monitoring are crucial for early detection of progression and complications and for early diagnosis of evolving disease. Recognition of syndromes of clinical significance, including MGRS and MGNS, is equally important because toxicity from the M-protein requires active treatment even in the absence of overt neoplasia.

The modern classification of plasma cell dyscrasias is therefore continuously evolving, driven by molecular discoveries and the identification of atypical or particularly high-risk clinical phenotypes. The principal entities are discussed in detail in dedicated pages, while this general overview provides a current global framework essential for interpreting the diagnostic landscape and planning clinical management.

Epidemiology and Risk Factors

Plasma cell dyscrasias are a group of disorders whose incidence is steadily increasing worldwide, principally because of progressive population aging and improved diagnostic techniques. Epidemiologically, these conditions show a marked predominance in middle-aged and older people: median age at diagnosis frequently exceeds 65 to 70 years for both MGUS and multiple myeloma. The prevalence of MGUS in people over 50 is approximately 3%, rises to about 5.3% in those aged at least 70 years and to about 7.5% in those aged at least 85 years, while multiple myeloma accounts for about 10% of all hematologic malignancies and 1 to 2% of all malignant neoplasms.

Geographically, substantial differences in incidence are observed: MGUS and multiple myeloma are more frequent in populations of African and African American ancestry than in White populations and are much rarer in Asian populations. This pattern suggests an important genetic contribution, although environmental factors and socioeconomic and healthcare conditions also influence the observed variability.

Risk factors are not uniform across all entities. For MGUS and multiple myeloma, the best documented associations are advanced age, male sex, African ancestry and a family history of MGUS or myeloma; additional associations depend on the specific disorder and cannot be generalized to the entire group.

It is important to emphasize that, even when risk factors are present, the absolute probability of developing a plasma cell dyscrasia remains relatively low in the general population, and in most cases no specific cause of the pathological clone can be identified.

The role of specific genetic factors is becoming increasingly clear through genome-wide studies: polymorphisms and variants have been identified in genes involved in immune-response regulation, DNA repair and control of cell proliferation. These variants may increase individual susceptibility but are not considered determining causes or predictive at the individual level.

Taken together, these findings suggest that plasma cell dyscrasias arise from a complex interaction among genetic predisposition, environmental factors and stochastic processes of mutation accumulation with age. This multifactorial model explains, at least in part, the marked epidemiological and clinical heterogeneity encountered in everyday practice.

Etiology, Pathogenesis and Pathophysiology

The pathogenesis of plasma cell neoplasms includes acquired genetic abnormalities affecting a plasma cell or its B-cell progenitor and causing loss of normal proliferative and apoptotic control. The principal molecular drivers include:

• Chromosomal translocations involving immunoglobulin loci, particularly IgH at chromosome 14q32, with activation of key oncogenes (CCND1, FGFR3/MMSET, MAF); MYC abnormalities are generally secondary progression events
• Point mutations and deletions affecting tumor suppressor genes (TP53, RB1) and intracellular signaling genes (NRAS, KRAS, BRAF, DIS3)
• Numerical abnormalities such as hyperdiploidy, deletion of 13q and gain of 1q, which contribute to genomic instability and clonal heterogeneity

These events, often acquired sequentially over many years, provide the basis for initiation and progression of the pathological plasma cell clone.

Documented risk factors vary according to the specific entity and are neither necessary nor sufficient causes. For MGUS and multiple myeloma, advanced age, male sex, African ancestry and family history are established associations; the contribution of other exposures or conditions is not uniform and cannot be generalized to all plasma cell dyscrasias.

Pathogenetically, the transition from physiology to disease is insidious and multistep. A driver genetic event, often clinically silent for years, generates a B-cell or plasma cell clone with proliferative advantages and resistance to apoptosis. Initially held under immune control, as in MGUS, the clone may subsequently accumulate further genetic lesions, lose immune surveillance and acquire invasive properties, the capacity to produce large amounts of monoclonal protein and the potential to cause organ damage. The principal pathogenetic mechanisms include:

• Deregulation of signaling pathways (NF-kB, PI3K/AKT/mTOR, MAPK) that sustain proliferation, survival and resistance to cell-death signals
• Pathological interaction with the bone marrow microenvironment: neoplastic plasma cells exploit stromal cells, cytokines (IL-6, VEGF, BAFF, APRIL), osteoclasts and immune cells to promote growth, angiogenesis and immune evasion
• Promotion of genomic instability and clonal diversity, with the emergence of more aggressive and treatment-resistant subclones
• Altered synthesis and secretion of monoclonal immunoglobulins or their fragments, which cause direct and indirect toxic effects on tissues

These pathogenetic processes, initially confined to the bone marrow compartment, may progressively involve other organs and systems and produce systemic clinical manifestations.

From a pathophysiological perspective, monoclonal burden and plasma cell proliferation produce several mechanisms of injury:

• Suppression of physiological hematopoiesis, causing anemia, cytopenias and an increased risk of infection
• Skeletal damage through osteoclast stimulation and osteoblast inhibition, leading to osteolysis, pain, pathologic fractures and hypercalcemia
• Renal failure, caused by formation of light-chain casts in the tubules, amyloid or nonfibrillar deposits and other mechanisms of glomerular, tubular or interstitial injury
• Secondary immunosuppression caused by suppression of polyclonal immunoglobulin synthesis and involvement of bone marrow immune cells
• Extramedullary organ damage through deposition phenomena (AL amyloidosis, light-chain or heavy-chain deposition diseases, cryoglobulinemia), viscous and toxic effects of the M-protein, and neurologic, cutaneous or vascular complications

The variability and combination of these processes produce the broad clinical spectrum of plasma cell dyscrasias, from asymptomatic indolent conditions to rapidly progressive and fatal disease.

It should be emphasized that the pathophysiology of plasma cell dyscrasias continues to evolve with advances in genomic and translational research. Their natural history is now recognized as nonlinear: there may be prolonged latent periods, phases of accelerated progression and, in some cases, coexistence of different clones in the same patient, or intrapatient heterogeneity. Integrated interpretation of genetic, molecular, clinical and environmental data is central to a modern understanding of plasma cell dyscrasias and strategies for prevention, diagnosis and treatment.

Clinical Features, Diagnosis and Investigations

The clinical picture of plasma cell dyscrasias is extraordinarily heterogeneous, reflecting the diversity of included entities and the multiplicity of underlying pathophysiological mechanisms. In many cases, particularly precursor conditions such as MGUS and smoldering myeloma, the disorder is entirely asymptomatic and is discovered incidentally through routine blood tests that identify a serum monoclonal component or laboratory abnormality. Progression to more advanced or aggressive stages, however, causes systemic manifestations resulting from tumor proliferation, toxic effects of the monoclonal component or deposition phenomena and organ injury.

The principal symptoms and signs include:

• Fatigue and progressive weakness, often related to anemia and bone marrow infiltration
• Bone pain, localized or diffuse and typically affecting the spine, ribs and long bones, which may progress to pathologic fractures and skeletal deformities
• Recurrent infections, especially bacterial infections, due to marked secondary immunosuppression caused by reduced synthesis of polyclonal immunoglobulins
• Renal symptoms (edema, oliguria, acute or chronic renal failure), often caused by light-chain tubular injury or amyloid deposition
• Neurologic symptoms (paresthesias, peripheral neuropathy, altered mental status), secondary to deposition of the M-protein, hyperviscosity phenomena or direct involvement of nerve plexuses
• Bleeding manifestations, caused by thrombocytopenia or coagulation abnormalities induced by the monoclonal component
• Symptoms of hyperviscosity syndrome (headache, dizziness, visual disturbances, epistaxis), typical of disorders with high production of IgM (Waldenstrom macroglobulinemia) or IgA
• Systemic manifestations caused by deposition (amyloidosis, AL amyloidosis, cryoglobulinemia, light-chain or heavy-chain deposition diseases), which affect the heart, kidneys, peripheral nervous system, skin and gastrointestinal tract

The clinical presentation may be monosymptomatic or polymorphic, and diagnosis is often delayed until potentially irreversible complications have developed.

A detailed medical history should investigate family history, recurrent infections, skeletal, bleeding or neurologic symptoms, unintentional weight loss and signs of organ failure. The physical examination may reveal pallor, bone masses, skeletal deformities, hepatomegaly, splenomegaly, signs of heart failure or peripheral neuropathy.

The diagnostic suspicion often arises from detection of a serum monoclonal component, an M spike on protein electrophoresis, or laboratory abnormalities such as anemia, hypercalcemia, renal failure or Bence Jones proteinuria. In patients with systemic symptoms or organ injury, suspicion should be strengthened and should prompt a sequential and rational diagnostic approach.

The sequence of investigations follows this general framework:

• Complete blood count: to assess anemia, leukopenia and thrombocytopenia as signs of bone marrow infiltration
• Serum chemistry: measurement of creatinine, urea, calcium, albumin, beta2-microglobulin and LDH to estimate organ damage and disease stage
• Twenty-four-hour urine protein and serum free light-chain measurement and assessment of the urinary monoclonal component by electrophoresis and immunofixation to document production and excretion of the monoclonal component
• Serum electrophoresis and immunofixation: to identify and type the M-protein, essential for diagnosis and monitoring
• Bone marrow assessment (aspiration and biopsy): to evaluate the percentage and cytomorphologic and immunophenotypic features of plasma cells, as well as cytogenetic abnormalities and molecular mutations
• Radiologic imaging: conventional radiography, CT, magnetic resonance imaging and PET to identify osteolytic lesions, focal plasmacytomas, extramedullary involvement or skeletal complications
• Specific investigations when deposition syndromes are suspected: tissue biopsies (renal, cardiac, gastrointestinal, nerve) with special stains to identify deposited amyloid or immunoglobulins

The diagnostic pathway is adapted to the clinical and laboratory findings and aims to confirm the dyscrasia, define the nature, quantity and location of the clone, identify the type of monoclonal component produced and establish the presence and severity of organ damage.

The definitive diagnosis and classification require integration of clinical, laboratory and imaging data according to international criteria such as IMWG and WHO. In precursor conditions such as MGUS and SMM, diagnosis is based on quantification of the M-protein, the percentage of bone marrow plasma cells and the absence of organ damage. In overt plasma cell neoplasms, including multiple myeloma and plasmacytomas, in deposition syndromes and, separately, in Waldenstrom macroglobulinemia, the presence of organ damage, the type of immunoglobulin produced, cytogenetic abnormalities and treatment response define additional clinical and prognostic subclassifications.

Early and accurate identification of a plasma cell dyscrasia, assessment of progression risk, diagnosis of complications and selection of the most appropriate treatment require a multidisciplinary approach and specialist hematology centers. At every stage, collaboration among clinicians, pathologists, geneticists, radiologists and nephrologists is fundamental to an optimal diagnostic and therapeutic pathway.

Treatment, Prognosis and Complications

Treatment of plasma cell dyscrasias requires an individualized strategy based on the type of dyscrasia, risk of progression, presence of organ damage and the patient's general condition. Clinical management differs radically between precursor forms such as MGUS, characterized by indolence and the need for follow-up alone, and overt plasma cell disorders such as multiple myeloma or AL amyloidosis, as well as the distinct lymphoplasmacytic neoplasm represented by Waldenstrom macroglobulinemia, which, when active, symptomatic or associated with organ damage, require clone-directed treatment and multidisciplinary management.

Management of precursor forms is differentiated: MGUS remains under surveillance without clone-directed therapy; monitoring remains appropriate for SMM that is not high risk, whereas subcutaneous daratumumab is an approved option for selected patients with high-risk SMM according to applicable regulatory criteria. Other early interventions remain under investigation in clinical trials. Follow-up does not prevent biological progression, but it allows timely recognition of a myeloma-defining event and prevents delays in treatment.

In symptomatic overt disease, treatment is complex and is based on combinations of chemotherapy, immunotherapy, targeted agents and, in eligible patients, autologous stem cell transplantation. Regimens have evolved substantially in recent years with the introduction of new drug classes:

• Immunomodulatory agents (lenalidomide, pomalidomide)
• Proteasome inhibitors (bortezomib, carfilzomib, ixazomib)
• Monoclonal antibodies (daratumumab, isatuximab, elotuzumab)
• High-dose corticosteroids (dexamethasone)
• Conventional chemotherapy agents (melphalan, cyclophosphamide, bendamustine)
• Novel targeted therapies (BCL2 inhibitors, anti-BCMA agents, CAR T cells, bispecific antibodies)

The choice of treatment combination and sequence is guided by prognostic factors, comorbidities, patient frailty and treatment response. In multiple myeloma, in particular, autologous transplantation and access to maintenance therapy have significantly improved long-term survival.

Deposition disorders, including AL amyloidosis and light-chain or heavy-chain deposition diseases, require a specific approach directed at reducing production of the pathological component and preventing progression of organ damage. In these settings, the speed of therapeutic response is crucial to functional prognosis, especially when advanced cardiac or renal involvement is present.

Treatment of complications is central to the management of plasma cell dyscrasias because many clinical manifestations and deaths result from secondary effects of the disease or its therapies:

• Anemia and cytopenias: depending on etiology and severity, may require transfusions, erythropoietic support and measures to prevent or treat infections
• Skeletal complications: are managed with bisphosphonates, denosumab, palliative radiotherapy and orthopedic surgery for pathologic fractures
• Renal failure: requires early nephroprotective measures, control of proteinuria and dialysis in severe cases
• Hypercalcemia: is treated with hydration and antiresorptive agents; calcitonin may be added in severe cases, whereas corticosteroids are mainly indicated in calcitriol-mediated forms
• Immunosuppression: requires appropriate vaccination and, in selected patients according to risk and treatment, antimicrobial prophylaxis and active management of infections
• Hyperviscosity syndrome: may require urgent plasma exchange in disorders with very high IgM or IgA concentrations
• Neurologic and deposition-related manifestations: individualized approaches include symptomatic therapies, physiotherapy and specialist interventions involving the heart, nervous system, skin, liver and gastrointestinal tract

The complexity and frequency of complications require multidisciplinary follow-up, often at specialist hematology centers.

The prognosis of plasma cell dyscrasias is extremely variable. Precursor disorders such as MGUS have a very low annual risk of progression, approximately 1%, while multiple myeloma and other overt forms have shown progressively longer overall survival in recent years because of new drugs and optimized treatment pathways. Their natural history nevertheless remains burdened by relapse, infectious complications, organ damage and, in some patients, progression to chemoresistant disease and more aggressive secondary forms such as extramedullary plasmacytoma and plasma cell leukemia.

The principal prognostic factors include:

• Type and quantity of the monoclonal component
• Cytogenetic and molecular characteristics of the clone
• Presence and severity of organ damage at diagnosis
• Response to therapy and depth of remission
• Patient age, performance status and comorbidities

Refinement of prognostic stratification systems, including ISS, R-ISS and scores for amyloidosis and specific hematologic neoplasms, now permits unprecedented individualization of treatment and follow-up.

In summary, management of plasma cell dyscrasias requires a comprehensive and dynamic approach that integrates therapeutic innovation, prevention and treatment of complications, and support for patients and families. Future perspectives focus on precision medicine, early diagnosis of high-risk forms, prevention of progression and definitive treatment of aggressive disease through advances in cellular therapies and genomic platforms.

References
1. Rajkumar SV et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncology. 15, 12, 2014, e538-e548.
2. Kumar S et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncology. 17, 8, 2016, e328-e346.
3. Dimopoulos MA et al. EHA-EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma. Nature Reviews Clinical Oncology. 22, 9, 2025, 680-700.
4. Gertz MA. Waldenström macroglobulinemia: 2023 update on diagnosis, risk stratification, and management. American Journal of Hematology. 98, 2, 2023, 348-358.
5. Kyle RA et al. Prevalence of Monoclonal Gammopathy of Undetermined Significance. New England Journal of Medicine. 354, 13, 2006, 1362-1369.
6. Gertz MA. Immunoglobulin light chain amyloidosis: 2024 update on diagnosis, prognosis, and treatment. American Journal of Hematology. 99, 2, 2024, 309-324.
7. Leung N et al. The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. Nature Reviews Nephrology. 15, 1, 2019, 45-59.
8. Dispenzieri A. POEMS syndrome: 2021 update on diagnosis, risk-stratification, and management. American Journal of Hematology. 96, 7, 2021, 872-888.
9. Castillo JJ et al. The evaluation and management of monoclonal gammopathy of renal significance and monoclonal gammopathy of neurological significance. American Journal of Hematology. 96, 7, 2021, 846-853.
10. Caers J et al. Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel. Journal of Hematology & Oncology. 11, 1, 2018, 10.